Ranbaxy net falls 5% despite 15% rise in topline - Views on News from Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks


Login Failure
(Please do not use this option on a public machine)
  Sign Up | Forgot Password?  

Ranbaxy net falls 5% despite 15% rise in topline

Jul 29, 2000

Despite a 15% rise in the topline, Ranbaxy's bottomline has dropped 5% in the second quarter of the current year.

(Rs m) 2QFY99 2QFY00 Change
Sales 3,695 4,236 14.6%
Profit before Tax 464 437 -5.8%
Tax 39 33 -15.4%
Profit after Tax/(Loss) 425 404 -4.9%
Net profit margin (%) 11.5% 9.5%  
No. of Shares (m) (eoy) 115.9 115.9  
Diluted no. of shares (m) 115.9 115.9  
Diluted Earnings per share* 14.7 13.9  

The reasons for this are not far to seek. With dependence on antibiotics at around 55% of the company's turnover, the margins are bound to be under pressure due to heavy congestion in the antibiotics market.

Surprisingly, the company's domestic sales have grown over 16.5% in the current quarter while the exports have grown by 12.6%. One reason for this is the fact that the company is changing the compostion of its exports from bulk actives to generic formulations and in the transition period the growth has fallen.

This is the second consecutive quarter where the company's profit has fallen and with the overall pharmaceutical market, especially the antibiotic market, still in a swoon not much can be expected from the remaining quarters as well. Perhaps the only way out for the company would be the licensing of the BPH compound, but around nine months ago at an analysts meet the management had clarified that the development of the compound would take around eighteen months.

The stock quotes at Rs 551 which implies an earning multiple of 39.6 times second quarter annualised earnings.

Equitymaster requests your view! Post a comment on "Ranbaxy net falls 5% despite 15% rise in topline ". Click here!


More Views on News

Sorry! There are no related views on news for this company/sector.

Most Popular

Why We Picked This Small-cap Stock for Our Hidden Treasure Subscribers (Profit Hunter)

Sep 17, 2020

This leading household brand will profit big time in a post covid world.

My Top Stock to Buy in this Market Selloff (Profit Hunter)

Sep 22, 2020

The recent correction offers a great opportunity to buy this high conviction smallcap stock.

Can the Nifty Fall to 10,200? (Fast Profits Daily)

Sep 24, 2020

The Nifty has reached an important support level today. If it breaks then we could see further downside.

What Do the Charts Say About Buying Smallcaps Now? (Fast Profits Daily)

Sep 18, 2020

Everyone seems to be excited about buying smallcaps now...but is it the right thing to do? What do the charts tell us? Find out in this video...


Covid-19 Proof
Multibagger Stocks

Covid19 Proof Multibaggers
Get this special report, authored by Equitymaster's top analysts now!
We will never sell or rent your email id.
Please read our Terms


Apr 1, 2015 (Close)


  • Track your investment in RANBAXY LAB with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks